248 related articles for article (PubMed ID: 10390194)
41. Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs. interleukin-2.
Chen YM; Ting CC; Peng JW; Yang WK; Yang KY; Tsai CM; Perng RP
J Interferon Cytokine Res; 2000 Jan; 20(1):31-9. PubMed ID: 10670650
[TBL] [Abstract][Full Text] [Related]
42. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
43. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
44. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.
Besser MJ; Schallmach E; Oved K; Treves AJ; Markel G; Reiter Y; Schachter J
Cytotherapy; 2009; 11(2):206-17. PubMed ID: 19148842
[TBL] [Abstract][Full Text] [Related]
45. Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors.
Shimizu Y; Iwatsuki S; Herberman RB; Whiteside TL
Cancer Immunol Immunother; 1991; 32(5):280-8. PubMed ID: 1847844
[TBL] [Abstract][Full Text] [Related]
46. Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.
Musso A; Catellani S; Canevali P; Tavella S; Venè R; Boero S; Pierri I; Gobbi M; Kunkl A; Ravetti JL; Zocchi MR; Poggi A
Haematologica; 2014 Jan; 99(1):131-9. PubMed ID: 24162786
[TBL] [Abstract][Full Text] [Related]
47. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
48. Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study.
Ruco LP; Pomponi D; Pigott R; Stoppacciaro A; Monardo F; Uccini S; Boraschi D; Tagliabue A; Santoni A; Dejana E
Am J Pathol; 1990 Nov; 137(5):1163-71. PubMed ID: 1700619
[TBL] [Abstract][Full Text] [Related]
49. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen.
Mami-Chouaib F; Echchakir H; Dorothée G; Vergnon I; Chouaib S
Immunol Rev; 2002 Oct; 188():114-21. PubMed ID: 12445285
[TBL] [Abstract][Full Text] [Related]
50. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
51. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
52. MHC class-I-restricted auto-tumor-specific CD4+CD8- T-cell clones established from autologous mixed lymphocyte-tumor-cell culture (MLTC).
Wang P; Vánky F; Klein E
Int J Cancer; 1992 Jul; 51(6):962-7. PubMed ID: 1386348
[TBL] [Abstract][Full Text] [Related]
53. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
[TBL] [Abstract][Full Text] [Related]
54. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: reactivity toward the malignant clone.
Jacob MC; Piccinni MP; Bonnefoix T; Sotto MF; Couderc P; Bensa JC; Sotto JJ
Blood; 1990 Mar; 75(5):1154-62. PubMed ID: 2306520
[TBL] [Abstract][Full Text] [Related]
55. Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation.
Schwartzentruber DJ; Stetler-Stevenson M; Rosenberg SA; Topalian SL
Blood; 1993 Aug; 82(4):1204-11. PubMed ID: 8353284
[TBL] [Abstract][Full Text] [Related]
56. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors.
Miescher S; Whiteside TL; Moretta L; von Fliedner V
J Immunol; 1987 Jun; 138(11):4004-11. PubMed ID: 3108380
[TBL] [Abstract][Full Text] [Related]
57. Tumor-infiltrating lymphocytes isolated from a Ki-1-positive large cell lymphoma of the skin. Phenotypic characterization and analysis of cytokine secretion.
Reinhold U; Abken H; Kukel S; Goeden B; Uerlich M; Neumann U; Kreysel HW
Cancer; 1991 Nov; 68(10):2155-60. PubMed ID: 1655203
[TBL] [Abstract][Full Text] [Related]
58. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
Ramadan G
Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
[TBL] [Abstract][Full Text] [Related]
59. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
Haagen IA; van de Griend R; Clark M; Geerars A; Bast B; de Gast B
Clin Exp Immunol; 1992 Dec; 90(3):368-75. PubMed ID: 1281055
[TBL] [Abstract][Full Text] [Related]
60. Responses to T cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non-Hodgkin's lymphomas.
Kudoh S; Wang Q; Hidalgo OF; Rayman P; Tubbs RR; Edinger MG; Kolenko V; Panuto J; Bukowski R; Finke JH
Cancer Immunol Immunother; 1995 Sep; 41(3):175-84. PubMed ID: 7553687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
